Current Report Filing (8-k)
September 16 2014 - 4:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 16, 2014
SUNSHINE HEART, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or other jurisdiction of incorporation) |
|
001-35312
(Commission File No.) |
|
68-0533453
(IRS Employer Identification No.) |
12988 Valley View Road
Eden Prairie, Minnesota 55344
(Address of Principal Executive Offices) (Zip Code)
(952) 345-4200
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On September 16, 2014, Sunshine Heart, Inc. (Sunshine Heart or the Company) announced that follow-up data from six patients implanted with the C-Pulse® Heart Assist System at St. Lukes Hospital Mid America Heart Institute, as part of a FDA approved, North American Feasibility Trial, will presented by Dr. Sanjeev Aggarwal, MD, Director of Mechanical Circulatory Support at Saint Lukes Mid America Heart Institute. Prior to his clinical presentation at TCT Conference, Dr. Aggarwal will present these case studies and a COUNTER HF study update to the investment community at Sunshine Hearts fourth annual analyst and investor breakfast that begins at 7:00am (EDT) at the Grand Hyatt Washington on September 16, 2014. Dr. Christopher Bowles, PhD, Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, and Dr. William E. Cohn, MD, Texas Heart Institute, will also present at the breakfast. Following the event, the presentations will be available on the investor section of the Sunshine Heart website at http://ir.sunshineheart.com/index.cfm.
Limitation of Incorporation by Reference
In accordance with General Instruction B.2. of Form 8-K, this information including Exhibits 99.1, 99.2, 99.3 and 99.4, is furnished pursuant to Item 7.01 and shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Press Release - Sunshine Heart to Provide Case Studies from North American Feasibility Trial and Updates on OPTIONS HF and COUNTER HF at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference |
99.2 |
|
Presentation - Dr. Sanjeev Aggarwal, Director of Mechanical Circulatory Support at St. Lukes Mid America Heart Institute |
99.3 |
|
Presentation - Christopher Bowles, PhD, Artificial Heart Specialist at Royal Brompton and Harefield NHS Foundation Trust & Imperial College London |
99.4 |
|
Presentation - Dr. William E. Cohn, Director of Minimally Invasive Surgical Technology at Texas Heart Institute at St. Lukes Medical Center |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: September 16, 2014 |
|
SUNSHINE HEART, INC. |
|
|
|
|
By: |
/S/ JEFFREY S. MATHIESEN |
|
Name: |
Jeffrey S. Mathiesen |
|
Title: |
Chief Financial Officer |
2
EXHIBIT INDEX
Exhibit No. |
|
Description |
99.1 |
|
Press Release - Sunshine Heart to Provide Clinical Updates from the North American Feasibility Study and OPTIONS HF European Post-Market Study at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference |
99.2 |
|
Presentation - Dr. Sanjeev Aggarwal, Director of Mechanical Circulatory Support at St. Lukes Mid America Heart Institute |
99.3 |
|
Presentation - Christopher Bowles, PhD, Artificial Heart Specialist at Royal Brompton and Harefield NHS Foundation Trust & Imperial College London |
99.4 |
|
Presentation - Dr. William E. Cohn, Director of Minimally Invasive Surgical Technology at Texas Heart Institute at St. Lukes Medical Center |
3
Exhibit 99.1
Sunshine Heart to Provide Clinical Updates from the North American Feasibility Study
and OPTIONS HF European Post-Market Study at
2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference
EDEN PRAIRIE, Minn., September 16, 2014 (GLOBE NEWSWIRE) Sunshine Heart, Inc. (Nasdaq: SSH) announced today that follow-up data from six patients implanted with the C-Pulse® Heart Assist System at St. Lukes Hospital Mid America Heart Institute, as part of a FDA approved, North American Feasibility Study, will be presented later today by Dr. Sanjeev Aggarwal, MD, Director of Mechanical Circulatory Support at Saint Lukes Mid America Heart Institute. Prior to his clinical presentation at the TCT Conference, Dr. Aggarwal will present on a few of these patients who demonstrated clinical signs of myocardial recovery to the investment community at Sunshine Hearts fourth annual analyst and investor breakfast that begins at 7:00am (EDT) today at the Grand Hyatt Washington. Dr. Christopher Bowles, PhD, Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, and Dr. William E. Cohn, MD, Texas Heart Institute, will also present at the breakfast. Following the event, the presentations will be available on the investor section of the Sunshine Heart website at: http://ir.sunshineheart.com/index.cfm .
Myocardial Recovery in Ambulatory Heart Failure Patients Treated with the C-Pulse Cardiac Assist System: A Single-Center Experience, will be presented by Dr. Aggarwal in Session II: Mechanical Circulatory Support for Chronic CHF at 4:48 p.m. (EST) in Level 1, Room 152A/B. The patient data outlined on Dr. Aggarwals poster demonstrates that six NYHA Class III patients were successfully implanted with the C-Pulse System, using minimally invasive surgical (MIS) techniques, from July 2010 to April 2012 as part of the North American Feasibility Study. Safety endpoints at 6 months demonstrated that there were no device related deaths, neurological events, aortic disruptions, myocardial infarctions, and mediastinal infections. Quality of life was evaluated using two standard cardiac disease, self-assessments, MLWHF and KCCQ. One patient was transitioned to an implantable LVAD 97 days post C-pulse implantation due to worsening heart failure symptoms. Two patients remain clinically stable on C-Pulse support at 1178 and 982 days respectively, and have showed improvement in NYHA class, 6-minute walk test, and quality of life scores. The other three patients all demonstrated clinically significant improvement allowing for discontinuation of C-Pulse support with explantation of the percutaneous lead and continue to be followed. The mean duration of support was 659 days (range 534-793), the mean ejection fraction of blood pushed from the left ventricle out of the heart increased from 18.3% to 29.3%, and the mean reduction in Left Ventricle End Diastolic Dimension (LVEDD) was 1.1cm. Mean follow-up time post weaning was 335 days (range 52-565).
Dr. Bowles presentation provides a detailed case study of the first patient to be implanted with the C-Pulse System in the UK as part of the OPTIONS HF Study. OPTIONS HF is a post-market, multi-center, perspective, open label study for NYHA Class III and ambulatory Class IV heart failure patients being conducted in the EU. Dr. Bowles will discuss how the first patient qualified for the study, the patients heart failure history and classification, comorbidities, surgical outcome, and current condition.
Dr. Cohns presentation highlights C-Pulse II. C-Pulse II is a totally implantable device that has the same non-blood contacting, non-obligatory and MIS implantation characteristics as the current C-Pulse System alleviating the need for the percutaneous drive line.
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patients current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to be weaned from using the device due to sustained improvement in their heart failure condition as a result of the therapy.
Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.
About Sunshine® Heart
Sunshine Heart, Inc. (NASDAQ: SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on managements beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption Risk Factors and elsewhere in our filings with the SEC. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
For further information, please contact:
Investor: |
Media: |
Candice Knoll |
David Schull |
Blueprint Life Science Group |
Russo Partners |
T: +1-415-375-3340 |
T: +1-212-845-4271 |
|
|
Jeff Mathiesen |
Andreas Marathovouniotis |
Chief Financial Officer |
Russo Partners |
Sunshine Heart, Inc. |
T: +1-212-845-4235 |
T: +1-952-345-4200 |
|
Exhibit 99.2
|
SSH_logo_RGB©
2014 Sunshine Heart, Inc. TCT Breakfast Session September 16, 2014
www.sunshineheart.com
|
|
SSH_logo_RGBForward
Looking Statement This presentation contains forward-looking statements. All
forward-looking statements are managements present expectations of future
events and are subject to a number of risks and uncertainties. Various
factors could cause actual results to differ materially from these statements
including timing, clinical enrollment, clinical results, financing
availability, product sales and marketing or efficacy of products, and the
other risks set forth under the caption Risk Factors and elsewhere in our
periodic and other reports filed with the U.S. Securities and Exchange
Commission, including our Annual Report or Form 10-K for the fiscal year
ended December 31, 2013. Although the Company believes that the
forward-looking statements are reasonable and based on information currently
available, it can give no assurances that the Companys expectations are correct.
All forward looking statements are expressly qualified in their entirety by
this cautionary statement. Caution: C-Pulse ® is an investigational device.
The device is limited by federal (United States) law to investigational use
only. C-Pulse is a registered trademark of Sunshine Heart Inc. 1 © 2014
Sunshine Heart, Inc. | Slide
|
|
SSH_logo_RGBAgenda
Welcome Company Updates and Introductions OPTIONS HF Post Market
Multicenter Trial: Early Experience in Europe: a case study Harefield
Hospital UK Progress of Fully Implantable Pump Single Center Experience
with Patient Weaning from the US Feasibility Trial and thoughts from a
leading enroller in the COUNTER HF US Pivotal Study Can C- Pulse Use Lead To
Left Ventricular Recovery? Q&A Jeff Mathiesen Dave Rosa Christopher
Bowles, PhD Dr. William E. Cohn Dr. Sanjeev Aggarwal © 2014 Sunshine Heart,
Inc. 2
|
|
SSH_logo_RGBIntroductions
Dave Rosa © 2014 Sunshine Heart, Inc.
|
|
C-Pulse® System
Feasibility Study with a Non-Blood Contacting Extra-Aortic Counterpulsation
System in Patients with Moderate to Severe Ambulatory Heart Failure Sanjeev
Aggarwal, MD Director, Mechanical Circulatory Support Saint Luke's Mid
America Heart Institute Kansas City, MO Caution: Investigational device,
limited by Federal (or United States) Law to Investigational use.
|
|
Disclosures
No financial disclosures
|
|
C-Pulse Heart
Assist System Implantable components: Inflatable balloon placed around
the ascending aorta Epicardial ventricular sensing leads Percutaneous
driveline for system control and pneumatic actuation
|
|
C-Pulse Heart
Assist System Efficacy of counterpulsation therapy Implantation without
cardiopulmonary bypass Extravascular location without the need for systemic
anticoagulation Untethering Minimally invasive implantation
|
|
Goals of the
C-Pulse Feasibility Study A prospective, open label, single arm study
Demonstrate feasibility of device and procedure Assess learning curve
Refinement of technology and implant technique Safety Efficacy Support
conduct of subsequent pivotal trial
|
|
C-Pulse Trial:
Primary Safety Endpoints* (6 Months) Death Aortic Disruption Neurologic
Dysfunction Myocardial Infarction Major Infection Any other
device-related adverse event (as adjudicated by the CEC) *Device related
events as defined by INTERMACS event classifications
|
|
C-Pulse Trial:
Primary Efficacy Endpoints (6 Months) NYHA Class ranking Quality of Life
- Minnesota Living with Heart Failure Score (MLWHF) 6 Minute Walk Test
Peak VO2
|
|
C-Pulse Trial:
Other Efficacy Measures (6 Months) Hemodynamics/ RHC (CO/ CI, PAP, PCWP)
Quality of Life KCCQ Blood analysis (Na, Cr, Bili, Hgb, LFTs) Concomitant
cardiovascular medications Re-hospitalization (HF and all cause) Duration
of Support/ survival duration LOS (ICU/ discharge) Device usage/
compliance
|
|
Patient
Characteristics N = 20 Mean Age + SD
years (range) 56 + 9 (34-71) Gender Female 8 Male 12 Race African American 3
Caucasian 17 NYHA Class Ranking Class III 18 Class IV 2 INTERMACS
Classification 3. Stable but inotrope dependent 3 5. Exertion intolerant 8 6.
Exertion limited 7 7. Advanced NYHA Class III 2 Entiology Ischemic 8
Non-ischemic 12
|
|
Characteristics
of Implant Procedure Numbers are Mean SD (N), Median [Min, Max] for
Continuous variables and Percent (Count/N) for discrete variables.
Ambulatory Extra-Aortic Counterpulsation in Patients with Moderate to Severe
Chronic Heart Failure. Submitted for publication, Fe 2014. In review. Measure
All Patients (N=20) Incision to Dressing Time (minutes) 165.7 + 42.4 (19)
156.0 [98.0, 247.0] Anatomical Approach Full Sternotomy 70.0% (14/20) Partial
Sternotomy 10.0% (2/20) Right Parasternal 20.0% (4/20) Time in ICU (days) 2.2
+ 2.6 (19) 1.1 [0.6, 11.1] Time in Hospital (days) 9.9 + 4.2 (19) 8.0 [4.0,
19.0]
|
|
Device Related
Primary Safety Endpoints (6 months and 12 months) Death 0 at 30 days 1
at 6 months Aortic Disruption 1 at 137 days post implant Sternal wound
infection (mediastinitis) post surgery CEC adjudicated as major infection,
localized, procedure related Infection unresolved despite repeated surgical
interventions Aortic rupture occurred at time of third surgical
intervention Neurological Dysfunction: None Myocardial Infarction: None
Major Infection: 9 patients 8 exit site related 1 PICC line
|
|
Results: NYHA
Class 0% 20% 40% 60% 80% 100% I II III IV Baseline N=20 6 Mo N=15 12 Mo N=12
90% 10% 27% 20% 53% 25% 17% 58% p6Mo = 0.0005; p12Mo = 0.0002 Ambulatory
Extra-Aortic Counterpulsation in Patients with Moderate to Severe Chronic
Heart Failure. Submitted for publication, Feb 2014. In review.
|
|
Results: 6MWT
Ambulatory Extra-Aortic Counterpulsation in Patients with Moderate to Severe
Chronic Heart Failure. Submitted for publication, Feb 2014. In review. 0 100
200 300 400 500 Meters 276 296 337 p6Mo = 0.2239; p12Mo = 0.0425 Baseline
N=20 6 Mo N=15 12 Mo N=12
|
|
Results: MLWHF
Ambulatory Extra-Aortic Counterpulsation in Patients with Moderate to Severe
Chronic Heart Failure. Submitted for publication, Feb 2014. In review. 0 10
20 30 40 50 60 70 80 90 Score p6Mo = 0.0005; p12Mo = 0.0005 64.4 40.2 36.4
Baseline N=20 6 Mo N=15 12 Mo N=12
|
|
Results: KCCQ
Overall Ambulatory Extra-Aortic Counterpulsation in Patients with Moderate
to Severe Chronic Heart Failure. Submitted for publication, Feb 2014. In
review. 0 20 40 60 80 100 Score 41.0 65.6 67.4 p6Mo = 0.0002; p12Mo = 0.0024
Baseline N=20 6 Mo N=15 12 Mo N=12
|
|
Results: KCCQ
Clinical Score Ambulatory Extra-Aortic Counterpulsation in Patients with
Moderate to Severe Chronic Heart Failure. Submitted for publication, Feb
2014. In review. 0 20 40 60 80 100 Score 47.9 69.0 73.6 p6Mo = <0.0001;
p12Mo = 0.0093 Baseline N=20 6 Mo N=15 12 Mo N=12
|
|
Worsening HF
Hospitalizations Three (3) subjects had worsening heart failure
rehospitalizations Two were rehospitalized at 205 and 208 days Did not
maintain compliance with device usage One went to LVAD at 4 months Subject
ID Date of Implant HF Rehospitalizations Days to HF Event 08-001 21-Jul-10
14-Feb-11 208 08-003 26-Aug-10 18-Mar-11; 06-Aug-11 205 and 345 days 08-005
14-Jan-1 15-Feb-11; 07-Mar-11 33 and 52 days
|
|
Minimally
Invasive Surgical Approach
|
|
[LOGO]
|
|
[LOGO]
|
|
Additional
Observations 30.9 total patient-years of follow-up Diuretic doses
reduced/discontinued in 6 patients Inotropes discontinued in all
inotrope-dependent patients 4 patients successfully bridged to transplant
3 permanently discontinued from therapy after sustained improvement
|
|
Myocardial
Recovery Three of six patients showed clinically significant improvement
allowing for discontinuation of device support with explantation of the
percutaneous lead
|
|
Myocardial
Recovery Mean duration of support with C-Pulse was 659 days (range 534
793 days) Mean EF improved from 18.3% to 29.3% (one patient EF has improved
from 21% to greater than 40%) Mean reduction in LVEDD of 1.1cm No
readmissions for heart failure (follow up time range approximately 1-2.5
years)
|
|
Case #1 36
year old male NICM/ chronic systolic heart failure Significant exercise
intolerance, DOE Cpulse implant 4/10/2012 Discharged home POD#7 Pre
discharge echo demonstrated improvement in EF from 21% to >40% Last use
of device 9/25/2013 (533 days of support) PIL Explanted 4/2014 No
readmissions for heart failure (>350 days F/U)
|
|
[LOGO]
|
|
Case #2 RA 8
PAP 39/21/26 PCWP 11 CO/ CI 4.3/2.2 RA 7 PAP 47/25/31 PCWP 10 CO/CI 4.2/2.2
|
|
Conclusions
The C-Pulse Study demonstrates the feasibility and shows the preliminary
safety and efficacy of the C-Pulse System in patients with moderate to severe
heart failure FDA approved the IDE for the COUNTER HF randomized controlled
trial to demonstrate the effectiveness of the device
|
|
[LOGO]
|
Exhibit 99.3
|
Options HF C-Pulse System European
MultiCentre Study Case Presentation Dr Christopher Bowles Artificial Heart
Specialist Dr Nicholas Banner Consultant in Cardiology Transplant and
Mechanical Circulatory Support EU: C-Pulse is CE Marked US: Caution:
Investigational Device. Limited by Federal (or United States) law to
investigational use. 1
|
|
OPTIONS HF: Key Study Qualifications 2
Major Inclusion Criteria LVEF <35% Both ischemic/non-ischemic NYHA Class
III/Ambulatory Class IV On Optimal Medical Therapy Evaluated or have
CRT/CRT-D Major Exclusion Criteria Ascending aortic calcification or CABG
Mitral Valve Incompetence, Grade 4+ Aortic Valve Incompetence, Grade 2-4+
Confidential © 2014 Sunshine Heart, Inc.
|
|
54 yr old male patient Blood Group: A Rh D
Positive Height: 5ft 11inch Wt: 90.6kg Body Mass Index: 28 Confidential ©
2014 Sunshine Heart, Inc. 3
|
|
Background Acute myocardial infarction
whilst on vacation in 2002 (required resuscitation following cardiac arrest)
Primary percutaneous coronary intervention to right coronary artery (RCA)
& left anterior descending (LAD) artery (the latter was unsuccessful
resulting in LAD obstruction). Circumflex artery unobstructed Persistent New
York Heart Association Class III symptoms since 2002, fatigue and shortness
of breath on minimal exertion, loss of employment Atrial fibrillation treated
with: - AV node ablation: 1 Nov 2012 - Biventricular ICD pacemaker Type 2
diabetes Advanced heart failure with C-Pulse system intended as a destination
to heart transplantation 4 Confidential © 2014 Sunshine Heart, Inc.
|
|
Fulfilled multi-centre study entry criteria
C-Pulse implanted at Harefield Hospital, London on 16 June 2014 The first
C-Pulse case in the UK 5 Confidential © 2014 Sunshine Heart, Inc.
|
|
Post-operatively Uncomplicated
surgical procedure and short Intensive Care Unit stay (28 hours) Increased
inflammatory markers after surgery No source of infection identified Given
empirical antibiotic therapy Continuing signs of heart failure reflecting
poor pre-operative heart function Treated with high dose diuretics.
Discharged home on post operative day 22 Readmitted post operative day 47 to
52 with diarrhoea possibly due to antibiotic therapy Readmitted post
operative day 64 to 79 with deterioration in exercise capacity attributed to
heart rhythm disturbance Treated with short course of i.v. milrinone and
higher beta blocker dose 6 Confidential © 2014 Sunshine Heart, Inc.
|
|
Post operative day Distance walked in
six min (metre) Heart rhythm disturbance Functional capacity improvement as a
result of C-Pulse therapy 7 New ventricular ectopies are an early sign that
previously-thought ischemic (or lost) tissue is being perfused Confidential ©
2014 Sunshine Heart, Inc. 0 50 100 150 200 250 300 350 400 450 0 20 40 60 80
100
|
|
Post operative day Distance walked in
six min (metre) Heart rhythm disturbance Functional capacity improvement and
changes in heart function as a result of C-Pulse therapy Cardiac index
Litre/min/m2 With C-Pulse Without C-Pulse Attended daughters marriage 8
Confidential © 2014 Sunshine Heart, Inc. 0 50 100 150 200 250 300 350 400 450
0 20 40 60 80 100 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
|
|
Summary 54 year old man Advanced heart
failure due to ischaemic cardiomyopathy Uneventful C-Pulse implantation as a
bridge to heart transplant Has needed medical management for heart failure
since surgery Limited improvement in resting hemodynamics Yet marked
improvement in functional capacity possibly due to increased blood perfusion Remains
a suitable candidate on the active heart transplant list 9 Confidential ©
2014 Sunshine Heart, Inc.
|
|
Implications Caution: Single patient
experience Preliminary findings concur with large scale studies with
B-blockers1,2 and cardiac resynchronisation therapy pacemakers3 - Subtle
improvements in heart function can result in clinically important benefits,
i.e. improved exercise tolerance and quality of life. 1.NEJM 1996; 334:1349
2.NEJM 2001;344:1651 3. NEJM 2002;346:1845 10 Confidential © 2014 Sunshine
Heart, Inc.
|
Exhibit
99.4
|
Progress of the
Fully Implantable System Sep 16, 2014 www.sunshineheart.com
|
|
Internal
electro-hydraulic converter and TETS eliminate the percutaneous drive line
and associated infection risks. Non-blood contacting Non-obligatory C-Pulse
II Overview © 2014 Sunshine Heart, Inc. CAUTION: Investigational Device.
Limited by Federal (or United States) Law to Investigational Use. Fully
Implantable System
|
|
Internal
electro-hydraulic converter and TETS eliminate the percutaneous drive line and
associated infection risks. Non-blood contacting Non-obligatory No
percutaneous drive line © 2014 Sunshine Heart, Inc. CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use.
C-Pulse II Overview Fully Implantable System
|
|
Internal
electro-hydraulic converter and TETS eliminate the percutaneous drive line
and associated infection risks. Non-blood contacting Non-obligatory No
percutaneous drive line No implanted battery © 2014 Sunshine Heart, Inc.
CAUTION: Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. C-Pulse II Overview Fully Implantable System
|
|
Pramod Bonde,
et al. Yale University © 2014 Sunshine Heart, Inc. CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 4
|
|
Pramod Bonde et
al. Yale University © 2014 Sunshine Heart, Inc. CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 5
|
|
Eliminating the
driveline is not a new idea Circa 1985 © 2014 Sunshine Heart, Inc. CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 6
|
|
Arrow LionHeart
LVAD First clinical TETS system © 2014 Sunshine Heart, Inc. CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 7
|
|
Arrow LionHeart
LVAD First clinical TETS system © 2014 Sunshine Heart, Inc. CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 8
|
|
Arrow LionHeart
LVAD First clinical TETS system © 2014 Sunshine Heart, Inc. CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 9
|
|
Penn State
Arrow Lionheart summary Nov 9, 2003 23 male patients enrolled between Oct
1999 and Dec 2002 10/23 discharged home with device 8/23 alive at 2 years
1/23 alive at 3 years Mean duration 347 days (17-1259) 5/23 serious
infections (.17/patient year vs. .60/patient year REMATCH no deaths due to
infections) No serious TETs complications © 2014 Sunshine Heart, Inc.
CAUTION: Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 10
|
|
23 male
patients enrolled between Oct 1999 and Dec 2002 10/23 discharged home with
device 8/23 alive at 2 years 1/23 alive at 3 years Mean duration 347 days
(17-1259) 5/23 serious infections (.17/patient year vs. .60/patient year
REMATCH no deaths due to infections) No serious TETs complications Penn State
Arrow Lionheart summary Nov 9, 2003 © 2014 Sunshine Heart, Inc. CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 11
|
|
Where will
clinical implementation of TETS technology first find traction? © 2014
Sunshine Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or
United States) Law to Investigational Use. 12
|
|
© 2014 Sunshine
Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. 13
|
|
© 2014 Sunshine
Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. ? 14
|
|
© 2014 Sunshine
Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. SUNSHINE HEART C-pulse Extra-Aortic
Balloon Cuff 15
|
|
SUNSHINE HEART
C-pulse Extra-Aortic Balloon Cuff © 2014 Sunshine Heart, Inc. CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. Non-obligatory No blood contact so 16
|
|
SUNSHINE HEART
C-pulse II © 2014 Sunshine Heart, Inc. CAUTION: Investigational Device.
Limited by Federal (or United States) Law to Investigational Use. 17
|
|
Electrohydraulic
pump © 2014 Sunshine Heart, Inc. CAUTION: Investigational Device. Limited by
Federal (or United States) Law to Investigational Use. 18
|
|
C-Pulse II
Leveraging powerful synergies Minnetronix Cirtec Medical Systems Texas Heart
Institute At St. Lukes Episcopal Hospital © 2014 Sunshine Heart, Inc.
CAUTION: Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 19
|
|
Electrohydraulic
pump Cirtec Medical Systems Rapidly inflates and deflates the extra-aortic
balloon cuff (reproduces C-I physiology) EKG synchronized to provide
counter-pulsation Balloon passively empties in the event of pump or power
failure (essential) Leverages the incompressibility of silicone oil
Compliance reservoir incorporated into the base of the pump © 2014 Sunshine
Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. 20
|
|
Rapidly inflates and deflates the
extra-aortic balloon cuff (reproduces C-I physiology) EKG synchronized to
provide counter-pulsation Balloon passively empties in the event of pump or
power failure (essential) Leverages the incompressibility of silicone oil
Compliance reservoir incorporated into the base of the pump © 2014 Sunshine
Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. Electrohydraulic pump Cirtec Medical
Systems 21
|
|
C-Pulse II
Important IP progress © 2014 Sunshine Heart, Inc. CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 22
|
|
C-Pulse II
Important IP progress So no need for an implantable battery © 2014 Sunshine
Heart, Inc. CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. 23
|
|
Cirtec Medical
Systems Electrohydraulic pump- CAUTION: Investigational Device. Limited by
Federal (or United States) Law to Investigational Use. 24 © 2014 Sunshine
Heart, Inc.
|
|
How are we
going to power it? CAUTION: Investigational Device. Limited by Federal (or
United States) Law to Investigational Use. 25 © 2014 Sunshine Heart, Inc.
|
|
Trans-cutaneous
Energy Transfer System (TETS) DC battery pack outside the body DC current is
put through an oscillator to make AC AC current energizes external coil (1o)
to generate an oscillating magnetic field Oscillating magnetic field goes
through the skin Oscillating magnetic field is picked up by a tuned internal
coil (2o) resulting in induction of AC current AC current rectified into DC
used to run the internal device CAUTION: Investigational Device. Limited by
Federal (or United States) Law to Investigational Use. 26 © 2014 Sunshine
Heart, Inc.
|
|
Standard
transformer CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. 27 © 2014 Sunshine Heart, Inc.
|
|
Inductive
coupling through an air-gap CAUTION: Investigational Device. Limited by
Federal (or United States) Law to Investigational Use. Design minimizes risk
of skin heating 28 © 2014 Sunshine Heart, Inc.
|
|
July 10 1856 January 7 1943 Nikola Tesla
CAUTION: Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 29 © 2014 Sunshine Heart, Inc.
|
|
Newest systems
are: Smaller size so easier to implant More energy efficient so improved
battery life More tolerant of geometric misalignment Minnetronix Leaders in
Transcutaneous Energy Transfer Systems (TETS) CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 30
© 2014 Sunshine Heart, Inc.
|
|
Minnetronix
Leaders in Transcutaneous Energy Transfer Systems (TETS) CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 31 © 2014 Sunshine Heart, Inc.
|
|
Improvement in
TETS component geometry and function Minnetronix CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 32
© 2014 Sunshine Heart, Inc.
|
|
Improvement in
TETS component geometry and function Minnetronix CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 33
© 2014 Sunshine Heart, Inc.
|
|
How are we
going to power it? Where are we going to test it? CAUTION: Investigational
Device. Limited by Federal (or United States) Law to Investigational Use. 34
© 2014 Sunshine Heart, Inc.
|
|
CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. TEXAS HEART INSTITUTE at St. Lukes Episcopal Hospital ©
2014 Sunshine Heart, Inc. 35
|
|
THI Cardio
Vascular Research Lab ICU 36 CAUTION: Investigational Device. Limited by
Federal (or United States) Law to Investigational Use. © 2014 Sunshine Heart,
Inc.
|
|
Surgical
Implant and System Integration THIs Cardio Vascular Research Lab The
premiere large animal cardiovascular research lab in the world Non-clinical
and pre-clinical safety testing are required by the global regulations prior
to human trials' Domain dominance in development and implementation of heart
failure technology Successful acute system implantation (first generation)
CAUTION: Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. 37 © 2014 Sunshine Heart, Inc.
|
|
Minimally
Invasive Implantation Small incision Sternal-sparing No cardiopulmonary
bypass 38 CAUTION: Investigational Device. Limited by Federal (or United
States) Law to Investigational Use. © 2014 Sunshine Heart, Inc.
|
|
Recent Progress
-Bench-Top Tests, CPII versus CPI Typical Average power 3Watts Peak
Instantaneous 20W 39 CAUTION: Investigational Device. Limited by Federal (or
United States) Law to Investigational Use. © 2014 Sunshine Heart, Inc.
|
|
40 CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. © 2014 Sunshine Heart, Inc.
|
|
41 CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. © 2014 Sunshine Heart, Inc.
|
|
Recent Acute
animals (x2) 42 CAUTION: Investigational Device. Limited by Federal (or
United States) Law to Investigational Use. © 2014 Sunshine Heart, Inc.
|
|
Recent Chronic
animal 21 days continuous operation 43 CAUTION: Investigational Device.
Limited by Federal (or United States) Law to Investigational Use. © 2014
Sunshine Heart, Inc.
|
|
44 CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. © 2014 Sunshine Heart, Inc.
|
|
CAUTION:
Investigational Device. Limited by Federal (or United States) Law to
Investigational Use. CAUTION: Investigational Device. Limited by Federal (or
United States) Law to Investigational Use. © 2014 Sunshine Heart, Inc. 45
|
|
The SUNSHINE
HEART C-Pulse II has the potential to be the first completely self-contained
therapy for heart failure since the bi-ventricular pacer Lack of blood
contact and non-obligatory feature make it the most likely candidate to
leverage TETS in a mechanical circulatory assist device Pump innovation has
facilitated development of a novel technology, avoiding the safety and
regulatory risks of an implantable battery The system is well suited for
implantation off-pump through a small sternal sparing incision, making it
well suited for patients earlier in the course of heart failure Early
pre-clinical testing suggests the design is performing as intended and within
established safety parameters In summary 46 CAUTION: Investigational Device.
Limited by Federal (or United States) Law to Investigational Use. © 2014
Sunshine Heart, Inc.
|
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024